Keyora Antarctic Krill Oil EP-14: The Persistent Inflammation-Resolution Matrix: Phospholipid Omega-3 Across Metabolic-Adipose Inflammation, Resolution Biology, Vascular Residual Risk, and Response-Guided Escalation

Background Persistent low-grade inflammation is frequently described as though it were a single biological condition identifiable through one elevated laboratory marker and addressable through one broadly anti-inflammatory intervention. This interpretation is insufficient. Persistent inflammatory signaling can arise from substantially different biological contexts, including metabolic dysfunction, adipose-tissue stress, insulin resistance, vascular and endothelial activation, aging-associated biological change, persistent immune stimulation, infection, tissue injury, immune-mediated disease, environmental exposure, malignancy, and other disease-specific processes. Similar circulating inflammatory signals can therefore emerge from different upstream drivers. The presence of inflammation does not independently identify its cause. Likewise, an inflammatory biomarker does not reconstruct the cellular, tissue, lipid-mediator, resolution, or functional system that produced it. Keyora Antarctic Krill Oil EP-14 consequently defines persistent low-grade inflammation as a biological phenotype rather than a diagnosis. The central framework, Keyora [The Persistent Inflammation-Resolution Matrix], organizes interpretation through: persistent biological driver→ inflammatory activation→ measurable evidence object→ resolution context→ assigned response object→ functional meaning. The article further establishes Keyora [The Inflammation-Resolution Separation Rule], which distinguishes inflammatory suppression from active resolution and tissue recovery; Keyora [The Inflammatory Evidence Object Map], which separates acute-phase, cytokine, cellular, lipid-mediator, and functional evidence; and Keyora [The Biomarker-Function Separation Rule], which prevents biochemical change from being promoted automatically into human functional or clinical benefit. Within this architecture, Keyora Antarctic Krill Oil is positioned as a Phospholipid Omega-3 intervention rather than as a generic anti-inflammatory oil. Its principal biological relevance lies at the intersection of membrane fatty-acid availability, EPA-DHA-DPA substrate biology, inflammatory lipid mediators, and active resolution-related processes. The intervention is therefore matched to a defined biological task only after persistence, driver context, phenotype, and response object have been established. Objective The objectives of EP-14 are to: establish persistent low-grade inflammation as a heterogeneous phenotype rather than a single diagnosis; distinguish acute protective inflammation from persistent inflammatory signaling and chronic low-grade inflammation; establish duration, recurrence, persistence, and termination as biological dimensions distinct from inflammatory intensity; explain why a single elevated inflammatory marker cannot establish biological persistence; distinguish persistent drivers, recurrent activation, and incomplete termination as different potential mechanisms sustaining inflammation; establish why inflammatory signals do not independently reveal their biological cause; differentiate metabolic-adipose, immune or disease-specific, vascular, aging-associated, and environmental inflammatory contexts; identify disease-driven inflammation as a condition requiring etiological clarification rather than automatic nutritional interpretation; establish hs-CRP as a clinically useful systemic acute-phase evidence object rather than a complete inflammatory-system measurement; distinguish analytical sensitivity from biological specificity; define what hs-CRP can and cannot establish; separate systemic acute-phase proteins, cytokines, cellular immune responses, lipid-mediator biology, and functional outcomes; establish Keyora [The Inflammatory Evidence Object Map]; establish Keyora [The Biomarker-Function Separation Rule]; establish Keyora [The Inflammation-Resolution Separation Rule]; define the metabolic-adipose inflammatory phenotype through adipocyte dysfunction, immune participation, altered lipid handling, insulin resistance, and systemic inflammatory spillover; distinguish adiposity from adipose dysfunction; distinguish systemic inflammatory markers from direct evidence of adipose-tissue immune biology; integrate impaired adipose insulin restraint, increased lipolysis, fatty-acid flux, hepatic metabolic burden, and inflammatory signaling; establish baseline inflammatory state as a modifier of intervention-response interpretation; position metabolic-adipose inflammation as a relatively coherent Phospholipid Omega-3 intervention phenotype when lipid-metabolic and membrane-substrate tasks overlap; evaluate human EPA/DHA inflammatory evidence through CRP, hs-CRP, IL-6, TNF-alpha, cellular, and metabolic response objects; incorporate both positive and null human Omega-3 evidence; reject the assumption that membrane incorporation automatically establishes systemic anti-inflammatory efficacy; establish inflammation resolution as an active biological program rather than passive disappearance of inflammatory signaling; distinguish containment, transition, resolution execution, efferocytosis, tissue repair, and functional recovery; establish membrane phospholipid fatty-acid composition as one determinant of lipid-mediator substrate availability; preserve arachidonic-acid biology as functionally diverse rather than uniformly inflammatory; establish EPA, DHA, and n-3 DPA as complementary but non-identical long-chain n-3 substrate objects; integrate EPA-derived 18-HEPE biology; integrate DHA-derived 17-HDHA, 14-HDHA, and related mediator-substrate biology; integrate human n-3 DPA lipid-mediator evidence while preserving dose and preparation boundaries; establish EPA-DHA-DPA Phospholipid Omega-3 Architecture as a membrane-substrate framework rather than proof of complete clinical resolution; evaluate direct human Krill Oil inflammatory evidence separately from generic EPA/DHA evidence; preserve positive, null, and discordant Krill Oil outcomes as separate evidence objects; distinguish preparation-specific Krill Oil evidence from exact finished-Keyora efficacy; define the vascular-endothelial residual inflammatory phenotype; separate atherogenic lipid risk from inflammatory risk; establish residual inflammatory risk as a cardiovascular domain capable of persisting despite lipid improvement; integrate endothelial activation, immune-vascular crosstalk, and NO-related endothelial dysfunction without converting biomarker response into cardiovascular-event evidence; define hs-CRP as a clinically meaningful but nonspecific cardiovascular inflammatory-risk object; reconstruct exact Keyora one- and two-softgel Phospholipid Omega-3 exposure; distinguish twofold exposure from twofold biomarker or clinical response; establish stable-context persistence verification before phenotype assignment; operationalize the framework through Keyora [The Persistent-Inflammation Response and Escalation Algorithm]; define final decisions as Continue, Reclassify, Investigate, or Escalate. Persistent Inflammation Is a Phenotype, Not a Diagnosis Inflammatory signaling is an adaptive component of human biology. A successful acute response involves: trigger recognition→ inflammatory activation→ containment→ removal of threat or damaged material→ transition→ active termination→ tissue recovery. Inflammation therefore becomes pathological not simply because it occurs, but because its magnitude, location, driver, duration, recurrence, or termination becomes inappropriate. Persistent inflammation differs from acute inflammation primarily through continued or recurrent biological activity. A highly intense inflammatory response can be transient. A lower-intensity signal can remain biologically active for prolonged periods. Inflammatory intensity and inflammatory persistence are therefore different variables. Persistent Drivers, Recurrent Activation, and Incomplete Termination Persistent signaling can arise through several routes. A biological driver can remain active. Repeated metabolic, immune, tissue, or environmental stress can reactivate inflammatory pathways before complete return toward baseline. Alternatively, termination biology may remain incomplete. These mechanisms can overlap. The existence of persistent inflammation does not establish that failed resolution is the sole cause. This distinction is essential because only some persistent phenotypes contain a plausible downstream membrane-fatty-acid or lipid-mediator task relevant to Phospholipid Omega-3. Chronic Low-Grade Inflammation Chronic low-grade inflammation is defined by sustained lower-intensity inflammatory activity within a biological context. Its importance is not determined by intensity alone. Persistent lower-grade signaling can remain biologically relevant when associated with: metabolic dysfunction; adipose stress; insulin resistance; vascular disease; aging-associated biology; recurrent environmental exposure; immune dysregulation; disease-specific processes. The heterogeneity of these drivers is precisely why chronic low-grade inflammation should not itself be treated as one diagnosis. An Inflammatory Signal Does Not Identify Its Cause A systemic inflammatory signal sits downstream of its biological driver. Similar CRP or cytokine patterns can arise from: adipose dysfunction; metabolic stress; persistent infection; immune-mediated disease; tissue injury; malignancy; vascular disease; aging; smoking; environmental exposure. The correct Keyora sequence therefore begins upstream of the biomarker. The signal establishes measurable inflammatory activity. It does not establish the cause responsible for producing it. Disease-Driven Infla